Akari Therapeutics Enters Share Purchase Agreement

The latest update is out from Akari Therapeutics ( (AKTX) ).

On August 29, 2025, Akari Therapeutics entered into an Ordinary Share Purchase Agreement with White Lion Capital, allowing the company to sell up to $25 million in newly issued Ordinary Shares. This agreement provides Akari with flexibility in timing and amount of sales, contingent upon market conditions and regulatory approvals. Additionally, the company’s CFO, Torsten Hombeck, announced his resignation effective October 10, 2025, but will remain as a consultant until at least November 30, 2025, to ensure a smooth transition.

The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.

Spark’s Take on AKTX Stock

According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.

Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.

To see Spark’s full report on AKTX stock, click here.

More about Akari Therapeutics

Akari Therapeutics is a biopharmaceutical company focused on developing treatments for rare and orphan diseases, primarily through its pipeline of drug candidates targeting severe and debilitating conditions.

Average Trading Volume: 32,836

Technical Sentiment Signal: Sell

Current Market Cap: $26.32M

For detailed information about AKTX stock, go to TipRanks’ Stock Analysis page.